West Pharmaceutical Services posted broad-based growth in the second quarter, driven by strong demand for high-value biologics packaging and proprietary delivery components. Organic revenue increased 15%, and management reinstated its favorable long-term growth outlook, citing continued demand from biologics and GLP-1 therapies. Conestoga Capital Advisors highlighted the stock as a performance contributor in its Q2 2026 investor letter, noting the quarter signaled a return to normalized growth rates after several years of post-COVID de-stocking. Shares of West Pharmaceutical Services gained 45.93% over the past 52 weeks and closed at $351.02 on August 5, 2026, with a market capitalization of $24.7 billion.
West Pharmaceutical Services IncStrong demand for high-value biologics packaging and proprietary delivery components drove broad-based growth in Q2.
